Cybelle

Cybelle Drug Interactions

cyproterone + ethinylestradiol

Manufacturer:

Eurodrug

Distributor:

Zuellig Pharma
Full Prescribing Info
Drug Interactions
Effects of other medicaments on CYBELLE 2mg/0.035mg: Interactions can occur with drugs that induce microsomal enzymes which can result in increased clearance of sex hormones and which may lead to breakthrough bleeding and/or contraceptive failure. Women on treatment with any of these drugs should temporarily use a barrier method in addition to CYBELLE 2mg/0.035mg or choose another method of contraception. The barrier method should be used during the time of concomitant drug administration and for 28 days after their discontinuation.
If the period during which the barrier method is used runs beyond the end of the tablets in the CYBELLE 2mg/0.035mg pack, the next pack should be started without the usual tablet- free interval.
Substances increasing the clearance of CYBELLE 2mg/0.035mg (diminished efficacy of CYBELLE 2mg/0.035mg by enzyme-induction), e.g.: Phenytoin, barbiturates, primidone, carbamazepine, rifampicin, and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin and products containing St. John's wort).
Substances with variable effects on the clearance of CYBELLE 2mg/0.035mg, e.g.: When co-administered with CYBELLE 2mg/0.035mg, many HIV/HCV protease inhibitors and nonnucleoside reverse transcriptase inhibitors can increase or decrease plasma concentrations of estrogen or progestin. These changes may be clinically relevant in some cases.
Effects of estrogen/progestogen combinations on other medicaments: Estrogen/progestogen combinations like CYBELLE 2mg/0.035mg may affect the metabolism of certain other drugs. Accordingly, plasma and tissue concentrations may either increase (e.g. cyclosporin) or decrease (e.g. lamotrigine).
Other forms of interactions: Laboratory tests: The use of preparations like CYBELLE 2mg/0.035mg may influence the results of certain laboratory tests.
Concomitant use with the medicinal products containing ombitasvir / paritaprevir / ritonavir and dasabuvir, with or without ribavirin may increase the risk of ALT elevations (See Contraindications and Precautions). Therefore, users must switch to an alternative method of contraception (e.g., progestogen only contraception or non-hormonal methods) prior to starting therapy with this combination drug regimen. CYBELLE 2mg/0.035mg can be restarted 2 weeks following completion of treatment with this combination drug regimen.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in